TriFlo Cardiovascular focuses on minimally invasive transcatheter solutions to treat tricuspid valve regurgitation.
TriFlo Cardiovascular has raised $13.8M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in December 2021.
TriFlo Cardiovascular is headquartered in Huntington Beach, United States.
TriFlo Cardiovascular focuses on minimally invasive transcatheter solutions to treat tricuspid valve regurgitation.
TriFlo Cardiovascular is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"TriFlo Cardiovascular — Funding & Investors." VCBacked, December 22, 2021, https://www.vcbacked.co/company/triflo-cardiovascular. Accessed August 14, 2026.
VCBacked. (2021). TriFlo Cardiovascular — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/triflo-cardiovascular
{{cite web |title=TriFlo Cardiovascular — Funding & Investors |url=https://www.vcbacked.co/company/triflo-cardiovascular |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated